Morningside

Xealth Inc. is a digital health company that has developed a comprehensive platform enabling clinicians to integrate, prescribe, and monitor various digital health tools and programs directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, Xealth's platform allows care teams to efficiently order digital health solutions for patients, facilitating seamless communication through email or patient portals. The platform also provides functionality for monitoring patient engagement and analyzing the impact of these tools on patient outcomes. Additionally, Xealth supports non-clinical services, such as ride-sharing and food delivery, enhancing the overall patient experience and promoting greater utilization of digital health resources.

SimpliFed is a telehealth company founded in 2020 that focuses on providing virtual breastfeeding support to new and expectant parents. It addresses the challenges faced by these individuals, such as sleep deprivation and concerns about infant nutrition. SimpliFed offers a maternal care platform that delivers virtual-first care throughout the peri and postnatal periods. The company specializes in lactation and baby feeding support, as well as monitoring high-risk conditions like hypertension and gestational diabetes. By engaging with patients early, SimpliFed’s care navigators facilitate a comprehensive maternal care experience, allowing parents to receive timely answers to their questions about infant feeding through secure online and video connections.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

CairnSurgical is a company focused on creating innovative, patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. By utilizing patient imaging data alongside advanced 3D printing technologies, CairnSurgical develops image guidance devices that assist healthcare professionals in achieving improved surgical outcomes. The company's commitment to personalized medical solutions aims to transform the surgical experience for patients, ensuring that interventions are tailored to their specific anatomical needs.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, smart billing, and predictive analytics. Established in 2020 and headquartered in New York, the company aims to improve healthcare delivery for seniors by facilitating remote patient care across various settings, including skilled nursing facilities, homes, and ambulances. Curve Health's platform has successfully reduced patient transfers from skilled nursing facilities to emergency departments by over 50%. It streamlines care coordination between hospital systems and post-acute facilities, automates billing processes, and enhances the tracking of patient diagnoses and outcomes. By bridging existing gaps in healthcare delivery, Curve Health seeks to optimize resource allocation, minimize readmissions, and ensure a seamless experience for patients, ultimately leading to improved care quality and financial returns for healthcare providers.

Casana, officially known as Heart Health Intelligence Inc., is a healthcare technology company based in Rochester, New York, founded in 2018. It specializes in developing innovative solutions for heart health monitoring, primarily through its flagship product, the Heart Seat. This smart toilet seat is designed to facilitate effortless and continuous in-home health monitoring by capturing essential clinical measurements such as heart rate, blood pressure, cardiac output, ECG, and blood oxygenation. The Heart Seat integrates advanced sensors, including a single-lead ECG, embedded photoplethysmogram LEDs, and sensitive weight sensors, to monitor cardiac activity. By offering a cloud-connected platform, Casana enables healthcare practitioners to track patients' cardiac health beyond traditional clinical settings, thereby enhancing the management of chronic conditions and improving patient outcomes through reliable and consistent vital signs analysis.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Huckleberry makes behavioral expertise accessible and affordable to all families by combining AI with human experts, starting with children's sleep.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Innodem Neurosciences is a Canadian company founded in 2016 that specializes in developing artificial intelligence-driven mobile software designed to enhance communication for paralyzed and intubated patients through eye movements. The company’s flagship product, Pigio, utilizes advanced eye-tracking technology to facilitate interaction between patients and caregivers. Additionally, Innodem's technology serves as a digital biomarker tool that aids in the diagnosis and monitoring of neurodegenerative diseases. By enabling self-testing and tracking disease progression, the technology allows clinicians to assess treatment effectiveness and make informed adjustments to patient care. Overall, Innodem Neurosciences is dedicated to improving the quality of life for patients and establishing a patient-centric approach in healthcare.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CairnSurgical is a company focused on creating innovative, patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. By utilizing patient imaging data alongside advanced 3D printing technologies, CairnSurgical develops image guidance devices that assist healthcare professionals in achieving improved surgical outcomes. The company's commitment to personalized medical solutions aims to transform the surgical experience for patients, ensuring that interventions are tailored to their specific anatomical needs.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that specializes in developing digital diagnostics and therapeutics for assessing and monitoring children's cognitive development. The company's online application empowers parents, guardians, and caregivers to evaluate their child's behavior through a series of questions and short videos, providing scores and personalized recommendations. Cognoa's technology focuses on identifying early signs of developmental delays, such as autism, ADHD, and anxiety, thereby facilitating earlier diagnosis and intervention. By offering tools to track assessments and share insights with healthcare providers, Cognoa aims to enhance the decision-making capabilities of families while improving the overall outcomes for children at risk of behavioral health conditions.

IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.

Meissa Vaccines, Inc. is a pharmaceutical development company based in San Mateo, California, established in 2014. The company is dedicated to advancing vaccines for respiratory syncytial virus (RSV), rhinovirus, and human metapneumovirus, targeting significant unmet medical needs, particularly in pediatrics. Meissa Vaccines aims to address the burden of acute lower respiratory tract diseases and the common cold, which are major contributors to healthcare challenges worldwide. Their vaccine programs are designed not only to benefit children but also to have a positive impact across various age groups. By successfully developing vaccines for these viruses, the company seeks to reduce acute asthma exacerbations, alleviate missed school and workdays, and ultimately improve public health outcomes.

Medvance is a pioneer in the development of 3D printed medical implants, specifically using PEEK materials. The company specializes in creating medical 3D printing equipment and software tailored for advanced medical engineering. By providing innovative 3D printing solutions, Medvance aims to enhance medical outcomes for patients and healthcare professionals. Its strategic partnership with Evonik ensures a reliable supply of raw materials, further supporting Medvance's mission to deliver cutting-edge medical technologies. The company's initiatives are focused on improving healthcare in China and expanding its impact globally.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that specializes in brain health monitoring through innovative technology. The company has developed a multi-modal analytics platform that utilizes artificial intelligence, signal processing, and speech analytics to detect subtle changes in neurological health. By converting smartphones and tablets into effective brain health monitors, Aural Analytics enables the collection of objective and interpretable data. This technology supplements traditional functional rating scales used in clinical trials, providing continuous and reliable metrics for assessing the effectiveness of medical interventions. Aural Analytics' platform captures clinically relevant speech, fine motor, and linguistic samples to offer healthcare professionals accurate assessments of patient health, thereby enhancing the understanding of disease progression.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Allysta Pharmaceuticals, Inc., established in 2013 and based in Belmont, California, is a biopharmaceutical company specializing in the development of therapeutic peptides for eye diseases. Its primary focus is on treating inflammatory ocular surface disorders, with ALY688 being a key product in its pipeline. Allysta's portfolio also includes potential therapies for dry eye disease and liver disease, leveraging anti-inflammatory, anti-fibrotic, and cell-regenerative properties to address multiple diseases.

Apic Bio, Inc. is a gene therapy company based in Cambridge, Massachusetts, focused on developing innovative treatment options for rare and undertreated neurological and liver diseases. Established in 2017, the company is advancing several novel gene therapies, particularly targeting Alpha-1 Antitrypsin Deficiency, genetic Amyotrophic Lateral Sclerosis, and other central nervous system disorders. Apic Bio utilizes a gene therapy platform that employs a Dual Function Vector to silence the Z-AAT protein while augmenting the M-AAT protein, thereby addressing the underlying genetic issues. Through its targeted approach, Apic Bio aims to provide effective solutions for patients suffering from these challenging conditions.

Biothea Pharma focuses on transforming the treatment landscape for severe allergic reactions and anaphylaxis. The company is dedicated to developing needle-free treatments that offer healthcare professionals convenient and cost-effective alternatives to traditional methods. By prioritizing innovation in this critical area of healthcare, Biothea Pharma aims to enhance patient safety and improve the overall management of allergic conditions.

Elysium Health, Inc., established in 2014 and headquartered in New York, specializes in the development and sale of health supplements. The company focuses on two primary areas: cellular health and optimization, and long-term brain health. It offers a proprietary formulation of natural compounds, designed to support overall well-being at the cellular level, which is sold directly to consumers via its online platform. Additionally, Elysium provides a biological age testing solution.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that specializes in developing digital diagnostics and therapeutics for assessing and monitoring children's cognitive development. The company's online application empowers parents, guardians, and caregivers to evaluate their child's behavior through a series of questions and short videos, providing scores and personalized recommendations. Cognoa's technology focuses on identifying early signs of developmental delays, such as autism, ADHD, and anxiety, thereby facilitating earlier diagnosis and intervention. By offering tools to track assessments and share insights with healthcare providers, Cognoa aims to enhance the decision-making capabilities of families while improving the overall outcomes for children at risk of behavioral health conditions.

Keep is an innovative fitness platform that combines technology with a passion for sports, aiming to enhance the fitness experience for users. The company offers a comprehensive fitness solution that includes AI-assisted personalized curriculums, interactive live-streaming classes, and recorded fitness courses. These offerings are tailored to individual athletic levels, fitness goals, and daily workout habits. Additionally, Keep provides a range of smart fitness devices, gear, apparel, and nutritional products, creating an integrated ecosystem that bridges the physical and digital realms. By promoting a culture of fitness and encouraging community engagement, Keep seeks to inspire more individuals to embrace an active lifestyle.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

InSilixa, Inc. is a biotechnology company based in Sunnyvale, California, specializing in the development of high-performance CMOS biochips for molecular diagnostics. Founded in 2011, the company aims to democratize access to diagnostic testing by offering low-cost, high-performance solutions for DNA and protein-based testing. InSilixa focuses on creating point-of-care and near-patient platforms that enhance the efficiency and accessibility of genomic testing, particularly for the diagnosis of infectious diseases. By leveraging its proprietary semiconductor technology, InSilixa seeks to provide mass-deployable diagnostic tools that improve healthcare outcomes. The team comprises industry veterans with diverse expertise in semiconductor technology, biotechnology, medicine, and informatics.

DNAtrix, Inc. is a clinical-stage biotechnology company based in Houston, Texas, with an additional office in San Diego, California. The company specializes in developing virus-driven immunotherapies for cancer treatment, focusing initially on glioblastoma, a highly aggressive and currently untreatable brain tumor. Its lead product, DNX-2401, is a modified oncolytic virus derived from a common cold virus, designed to selectively target and kill cancer cells. This innovative approach has shown promising results, with over 35 patients treated and positive early outcomes reported. In addition to DNX-2401, DNAtrix is advancing other candidates such as DNX-2440 and DNX-2450 for solid tumors, as well as MYX-135 for hematological malignancies. The company also has a strategic partnership with Valo Therapeutics, further enhancing its research and development capabilities in the field of cancer immunotherapy.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that specializes in developing digital diagnostics and therapeutics for assessing and monitoring children's cognitive development. The company's online application empowers parents, guardians, and caregivers to evaluate their child's behavior through a series of questions and short videos, providing scores and personalized recommendations. Cognoa's technology focuses on identifying early signs of developmental delays, such as autism, ADHD, and anxiety, thereby facilitating earlier diagnosis and intervention. By offering tools to track assessments and share insights with healthcare providers, Cognoa aims to enhance the decision-making capabilities of families while improving the overall outcomes for children at risk of behavioral health conditions.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Kindstar Global (Beijing) Technology, Inc. is a Chinese enterprise that specializes in providing advanced clinical testing services, including esoteric diagnostic and laboratory testing, to hospitals across the country, particularly tertiary care facilities. Founded in 2003 and based in Wuhan, the company operates laboratory facilities in key cities such as Beijing, Shanghai, and Wuhan. Kindstar Global is committed to enhancing personalized medicine and specialized clinical services by developing innovative testing technologies and methods. In addition to diagnostic services, the company offers medical research, clinical trial services, and translational medicine studies, catering to the needs of physicians, medical institutions, and pharmaceutical companies. The organization adheres to international standards and guidelines to prioritize patient interests and healthcare provider requirements.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

HD Biosciences Inc. is a biotechnology company based in Shanghai, specializing in contract research for drug discovery. As a subsidiary of WuXi PharmaTech, it offers a comprehensive suite of services including assay development, high-throughput drug screening, structure-activity relationship analysis, and hit-to-lead biology solutions. The company has developed advanced technology platforms for drug discovery and has established long-term research agreements with major pharmaceutical clients, including Pfizer and Organon. HD Biosciences is recognized as a leader in biology-based drug discovery services in China, providing a range of capabilities from hit identification to in vivo pharmacology, thereby supporting the development of innovative pharmaceutical and biotechnology solutions.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...